Cytodyn Inc. cash flow statement CYDY

Annual Quarterly

In fiscal 2026, which ended May 31, 2026, Cytodyn Inc. used $17.3 million of cash from operations, down 96.8% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2027 Aug 31, 2026	FY 2026 May 31, 2026	FY 2025 May 31, 2025	FY 2024 May 31, 2024	FY 2023 May 31, 2023	FY 2022 May 31, 2022	FY 2021 May 31, 2021	FY 2020 May 31, 2020	FY 2019 May 31, 2019	FY 2018 May 31, 2018	FY 2014 May 31, 2014
Operating
Depreciation and amortization	—	0 -5.6%	0 -37.9%	0 -83.4%	0 -77.6%	1	—	2 +63.4%	1 +249.6%	0 -2.8%	0 +58.3%
Stock-based compensation	2 +19.3%	2 +1.1%	2 -33.3%	2 -43.5%	4 -31.5%	6 -40.2%	10 +59.3%	7 +93.3%	3 +162.5%	1 +7.1%	1 -74.1%
Operating cash flow	-23 -35.3%	-17 -96.8%	-9 +20.2%	-11 +56.3%	-25 +67.7%	-78 +33.9%	-118 -70.9%	-69 -36.3%	-50 -68.8%	-30	-7 -117.7%
Investing
Capital expenditures	—	—	—	—	—	—	0 +197.6%	0 +57.7%	0 +133.9%	—	0 +513.1%
Investing cash flow	—	0	—	—	—	—	-0 -197.6%	-0 +8.9%	-0 -304.9%	—	-0 +99.5%
Financing
Debt repaid	—	—	—	—	—	—	1	—	—	—	—
Short-term debt repaid	—	—	—	—	—	—	—	—	—	—	0
Financing cash flow	30 +2672.5%	17 +58.5%	11 -7.6%	12 -60.7%	30 -37.7%	48 -65.0%	137 +72.4%	80 +51.0%	53 +79.7%	29	—
Change in cash
Net change in cash	7 +145.1%	-0 -102.4%	2 +172.7%	1 -84.1%	5 +116.2%	-30 -251.2%	20 +81.5%	11 +384.1%	2 +510.9%	-1	—
Free cash flow	—	—	—	—	—	—	-118 -71.0%	-69 -36.3%	-50 -68.8%	—	-7 -118.1%
Ratios
Stock-based compensation to revenue	—	—	—	—	—	2,345.49%	—	—	—	—	—
Cash conversion	—	—	-2.34x	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CYDY (OTC)
Fiscal year ends: May 31
Incorporated in: DE
Headquarters: Vancouver, WA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1175680
Former names: CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.